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In the context of global drugs policy, Europe is often perceived 
as a liberal continent: several countries have taken the lead 
in controversial approaches such as harm reduction, as well 
as innovative drug-political solutions like ‘commissions for 
the dissuasion of drug abuse’ in Portugal, coffee shops in the 
Netherlands, and heroin-assisted treatment in Switzerland. 
However, the most recent innovations have come on the other 
side of the Atlantic. Bolivia was the first country in the world 
to withdraw from the UN Single Convention on Drugs in 2011, 
deeming it contrary to the (new) constitutional right to tradi-
tional uses of the coca leaf. In 2013 Uruguay became the first 
country to legalize marijuana for recreational use, and is now 
experimenting with an innovative regulation system. In the 
USA, a growing number of states are legalizing cannabis, for 
medical and recreational purposes. The presidents of Colom-
bia, Costa Rica, Guatemala and Mexico have put the issue of 
reforming the international drug prohibition regime on the 
agenda of the UN General Assembly Special Session (UNGASS) 
in 2016. Where is Europe amidst these upheavals, and what 
can we expect from the EU in the debate revolving around 
UNGASS?
Diverging Trends in Europe
The past ten to fifteen years of developments in the drug poli-
cies of European countries show two diverging trends: On the 
one hand drug use has increasingly become a public health 
and social issue, rather than a crime problem. On the other 
hand drug trafficking is increasingly seen as ‘organized crime’, 
to be countered by harsher punishments and more police 
cooperation. The integration of drug use and possession into 
[ 16 / 2015 ]
Summary
A quick overview of the past ten to fifteen years´ develop-
ments in drugs policies in Europe reveals two diverging 
trends: a public health and social policy track on the one 
hand, and a security policy track on the other. While as the 
future of drugs policy as a political field in its own right is 
being questioned in the European context, the EU has ex-
plicitly stated its objective of a greater involvement and role 
in international drugs policy. Apart from continuity in harm 
reduction and research promotion – i.e., EU’s key contri-
butions to global drugs policy – EU support to larger and 
deeper reconfigurations of the global drug prohibition re-
gime remains highly unlikely.
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broader health and social policy and the amalgamation of drug 
smuggling as security policy have led to predictions that drugs 
policy as a political field in its own right is about to disappear 
in Europe.1  
EU’s official policy on drugs2 is based on the principle of an 
equal emphasis on supply and demand reduction of drugs – 
meaning a balance between police and punishment on the one 
side, and prevention, treatment and harm reduction on the 
other. As drugs policy is subject to the principle of subsidiarity, 
the EU’s role and added value is reduced to one of coordina-
tion, international cooperation, research, monitoring and 
evaluation. 
Although the EU has intended to harmonize member-state pol-
icies and legislation on drugs, researchers disagree of whether 
EU-countries’ drugs policies have actually converged.3 The 
establishment of the European Monitoring Centre on Drugs 
and Drug Addiction (EMCDDA) in 1993 brought with it harmo-
nization of data collection at the European level, facilitating 
comparative and cross-country research. However, there have 
also been several parallel trends in European countries that 
have not necessarily been spurred by the EU.  
Decriminalization and Alternatives to Incarceration
In Europe, substance use offences are normally subject to 
administrative sanctions or lenient penalties such as fines, 
warnings, suspended processes or suspended prison sen-
tences.4 Moreover, several European countries have in recent 
years ‘decriminalized’ the possession of small amounts of 
drugs, whether by changing the legal status of the offence 
(criminal/ non-criminal), the category of the drug (when the 
category determines the penalty) or the size or amount of the 
penalty available.5 This trend towards decriminalization in 
Europe is mainly of three types: formal procedural law decrimi-
nalization; de facto and informal practices of not enforcing 
law; and substantive law decriminalization.6 
It has also become gradually more common in Europe to divert 
drug users from the criminal justice system through alterna-
tive measures that substitute for penal prosecution and incar-
ceration.7 Such measures can be applied at various points: the 
moment of arrest, before preventive prison, in sentencing, and 
when deciding on the release of an inmate.8 Generally, alterna-
tives are more commonly applied for problem drug users and 
addicted users than for occasional users, reflecting the view of 
addiction as a disease to be treated. Treatment is not merely 
an alternative for people who have committed drugs offences, 
but also for users who have committed acquisitive crimes. 
The suspension of prosecution or sentence usually depends 
on successful completion of treatment. Sometimes treatment 
comes in addition to, rather than instead of, punishment. In 
some cases treatment is court ordered; in others, the user’s 
consent is required.9 Moreover, many European countries have 
implemented drugs court models (Belgium, England, Ireland, 
Northern Ireland, Norway, Scotland and Wales). Since 2001, 
Portugal has operated with a comprehensive system of ‘com-
missions for the dissuasion of drug abuse’, through which drug 
users are channelled instead of being processed through the 
criminal justice system.10 
Drug Trafficking as a (Supra)National Security Matter
While drug use and addiction have been treated in incremen-
tally lenient ways as regards criminal justice, the securitization 
of drug trafficking as quintessential organized crime seems to 
have spurred stronger reactions from EU politicians. Already 
in 1999 heads of states at the Tampere European Council 
encouraged EU member states to enact additional legal provi-
sions to combat drug trafficking.  In the period 1999–2004 six 
member states (Denmark, Estonia, Greece, Ireland, Lithuania 
and UK) passed laws increasing the penalties for certain drug-
trafficking offences. In 2003 drug trafficking was defined as 
a pivotal threat to the security and stability of the EU as the 
main activity of organized crime, and its potential links to ter-
rorism.11 In 2004 the Council of the European Union passed a 
framework decision12 that called for stiffer penalties for traf-
ficking in illicit drugs, following the 1999 Tampere European 
Council Conclusions. After the framework decision, four more 
countries (Austria, Netherlands, Poland and Slovakia) passed 
laws aimed at bringing trafficking penalties in accordance with 
the provision.13  
Although large discrepancies still exist in EU countries’ legal 
frameworks on the matter of drug trafficking, organized crime 
has been a driver for harmonization of criminal law, as well 
as an important amplifier of cross-border police and judicial 
cooperation. For example, the adoption of the European 
1  EMCDDA (2012). 2012 Annual Report on the State of the Drugs Problem in 
Europe. Luxembourg : Publications Office of the European Union.
2 http://ec.europa.eu/dgs/home-affairs/what-we-do/policies/organized-
crime-and-human-trafficking/drug-control/index_en.htm
3 Chatwin, C. (2010). ‘Have recent evolutions in European governance 
brought harmonisation in the field of illicit drugs any closer?’, Drugs & Al-
cohol Today, 10 (4), 26-32.
4 EMCDDA (2009). Drug Offences: Sentencing and Other Outcomes. Selected 
Issue 2009. Luxembourg : Publications Office of the European Union.
5 EMCDDA (2011a). 2011 Annual Report on the State of the Drugs Problem 
in Europe. URL.: http://www.emcdda.europa.eu/publications/annual-
report/2011.
6 Böllinger, L. (2004). ‘Drug Law and Policy in Germany and the European 
Community:  Recent Developments’, Journal of Drug Issues, 34 (3), 491-510. 
7 EMCDDA (2005). ‘Alternatives to Imprisonment – Targeting Offending 
Problem Drug Users in the EU’, in Annual Report 2005, Selected Issue. Lux-
embourg: Publications Office of the European Union.
8 Giacomello, C. (2014): Propuestas de alternativas a la persecución penal 
y al encarcelamiento por delitos de drogas en América Latina. Documento 
informativo del IDPC. URL: http://www.undrugcontrol.info/es/temas/
proporcionalidad-de-las-penas/item/5504-propuestas-de-alternativas-
a-la-persecucion-penal-y-al-encarcelamiento-por-delitos-de-drogas-en-
america-latina
9 EMCDDA (2005).
10 EMCDDA (2011b): Drug Policy Profiles: Portugal. URL.: http://www.em-
cdda.europa.eu/publications/drug-policy-profiles/portugal
11 Council of the European Union (2003). A Secure Europe in a Better World: 
European Security Strategy. Brussels, 12 December 2003.
12 Council Framework Decision 2004/757/JHA of 25 October 2004 laying 
down minimum provisions on the constituent elements of criminal acts 
and penalties in the field of illicit drug trafficking. URL: http://db.eurocrim.
org/db/en/vorgang/44/ 
13 EMCDDA (2009).
3NUPI
Norwegian Institute of International Affairs 
C.J. Hambros plass 2D
PO Box 8159 Dep. NO-0033 Oslo, Norway
www.nupi.no |  info@nupi.no 
Established in 1959, the Norwegian Institute 
of International Affairs [NUPI] is a leading 
independent research institute on international 
politics and areas of relevance to Norwegian 
foreign policy. Formally under the Ministry of 
Education and Research, NUPI nevertheless 
operates as an independent, non-political 
instance in all its professional activities. 
Research undertaken at NUPI ranges from short-
term applied research to more long-term basic 
research.
   
16 · 2015
Arrest Warrant in 2002, meaning that arrest warrants are valid 
throughout the EU member states, Norway, Switzerland and 
Iceland, is seen as a landmark in international police coop-
eration. Europol’s supranational role and mandate seems to be 
ever-expanding. 
The EU’s International Drugs Policy Role
Not only has the EU contributed to international coordination 
and cooperation against drug trafficking at the European level, 
it has also increasingly engaged non-EU countries in its ‘fight 
against drugs’. This has included pressure on the EU’s eastern 
and southern neighbours to adopt its legislative framework, 
including the above-mentioned Council framework decision 
on minimum penalties, and a stepping up of police and judi-
cial cooperation against drug trafficking, organized crime and 
terrorism. In particular, the EU has sought to include non-EU 
countries in protecting its borders from such ‘security threats’. 
The EU has explicitly declared the objective of increasing its 
role and significance in international drug policy, in interna-
tional forums and in third countries.14 However, to have a clear 
voice in international relations, the EU needs to front matters 
with a certain consensus among its 28 member states. Chal-
lenges arise because of the sizable variation in drug-policy posi-
tions, with the Netherlands and Sweden as the two extremes. 
For example, two EU countries withdrew their support to the 
use of the term ‘harm reduction’ in the final version of the UN 
Political Declaration and Action Plan on Drugs in 2010.15  
The EU’s position on drugs policy has increasingly come to 
focus on promoting an ‘evidence-based approach’ through 
facilitating and supporting research. Public health principles 
have led to an emphasis on prevention, treatment and social 
reintegration. Despite internal disputes, the EU is the only 
region in the world which explicitly states risk and harm reduc-
tion as strategic objectives of its drugs policy. Police coopera-
tion and border management are, however, among the means 
on which the member states seem to find it easiest to agree 
– which is probably also an important reason for why these 
measures have dominated the EU’s approach to drug policy - 
or, rather, security policy. 
According to EMCDDA director Wolfgang Götz, the EU has an 
essential role to play at UNGASS 2016, to ‘bring ‘more Europe’ 
into world drugs policy’.16 Apart from harm reduction, research 
and human rights, issues which are already quite controversial 
in international drugs policy,17 this would entail a lot of dip-
lomatic manoeuvring. Thus, it seems rather unlikely that the 
EU will support any restructuring of the global drug prohibi-
tion regime. The drug-policy climate, also in ‘liberal’ countries 
like Portugal and the Netherlands, does not indicate that EU 
member states will opt for changes that cannot be made within 
the parameters of the current international legal framework. 
From an EU and European perspective, we are still far from any 
paradigm shift in international drugs policy. 
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